The College of Pharmacy at Dubai Medical University announces the participation of Dr. Bassam Atallah, Associate Dean for Clinical Affairs, in a Continuing Medical Education (CME) activity hosted by Medscape in May 2026. The program, titled “Beyond SGLT2 Inhibition: The Emerging Role of Dual SGLT1/2 Inhibition in Heart Failure,” brought together leading clinical voices to explore the next frontier in heart failure pharmacotherapy.

Dr. Atallah joined Dr. Biykem Bozkurt — former President of the Heart Failure Society of America and one of the foremost authorities in cardiovascular medicine — in a focused scientific discussion on the evolving landscape of heart failure and cardiometabolic disease management. His contributions centered on innovative treatment strategies and the shifting clinical paradigms shaping modern cardiovascular care.

Dual SGLT1/2 inhibition represents one of the most closely watched developments in cardiometabolic pharmacology, with growing evidence supporting its potential to extend the benefits of established SGLT2 inhibitor therapy across a broader patient population. Dr. Atallah’s engagement in this international forum reflects both his clinical expertise and his commitment to ensuring that global advances in therapeutics inform local and regional practice.

CME Activity Link:

Beyond SGLT2: Emerging Role of Dual SGLT1/2 Inhibition in Heart Failure — Medscape